Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 226-229

  De Smet, Julie ^a   Colin, Pieter ^a   De Paepe, Peter ^b   Ruige, Johannes ^c   Batens, Hélène ^c   Van Nieuwenhove, Yves ^c   Vogelaers, Dirk ^c   Blot, Stijn ^c   Van Bocxlaer, Jan ^a   Van Bortel, Luc M ^b   Boussery, Koen ^a  

^a Faculty of Pharmaceutical Sciences   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bariatric surgery; Fluoroquinolones; Pharmacokinetics

Indexed keywords

MOXIFLOXACIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; ROUX Y ANASTOMOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS BLOOD; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; OBESITY; ORAL DRUG ADMINISTRATION; STOMACH BYPASS;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; GASTRIC BYPASS; HUMAN EXPERIMENTATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OBESITY; QUINOLINES;

EID: 84859190477     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr436     Document Type: Article

References (10)

1. WHO. Obesity and Overweight. Fact Sheet No. 311. http://www.who.int/mediacentre/factsheets/fs311/en/ (2 September 2011, date last accessed).
2. O'Brien PE. Bariatric surgery: mechanisms, indications and outcomes.J Gastroenterol Hepatol 2010; 25: 1358-65.
3. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications.Obes Rev 2010; 11: 41-50.
4. De Smet J, Boussery K, Colpaert K et al. Pharmacokinetics of fluoroquinolones in critical care patients: a bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. J Chromatogr B 2009; 877:961-7.
5. FDA CDER. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf (2 September 2011, date last accessed).
6. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43: 83-90.
7. Ballow C, Lettieri J, Agarwal V et al. Absolute bioavailability of moxifloxacin. Clin Ther 1999; 21: 513-22.
8. Stass H, Dalhoff A. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. Infection 2005; 33: 29-35.
9. Stass H, Kubitza D, Moller JG et al. Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. Brit J Clin Pharmacol 2005; 59: 536-41.
10. Patti ME, Houten SM, Bianco AC et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity 2009; 17: 1671-7.